Tamarixetin ameliorates cerebral ischemia–reperfusion injury via suppressing nicotinamide adenine dinucleotide phosphate oxidase 2/nucleotide‐binding oligomerization domain like receptor family pyrin domain‐containing 3 inflammasome activation
Phytotherapy Research · 2024
DOI: 10.1002/ptr.8263 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytotherapy Research, 2024. Verfasst von Yanqiu Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Bioresource Research and Development of Liaoning Province, College of Life and Health Sciences, Northeastern University, Shenyang, …. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Reperfusion Injury, Inflammasomes, Rats, Sprague-Dawley. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Construction Project of Liaoning Provincial Key Laboratory, China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Tamarixetin, a natural dietary flavone, exhibits remarkable potential for the treatment of ischemic stroke. The present article aimed to explore the impact of tamarixetin on ischemic stroke and elucidate the underlying mechanisms. Effects of tamarixetin on ischemic stroke were evaluated in rats using the middle cerebral artery occlusion and reperfusion (MCAO/R) model, by assessing the neurological deficit scores, brain water content, brain infraction, and neuronal damage. The levels of proinflammatory cytokines, NLRP3 inflammasome activation, reactive oxygen species (ROS) production, and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase expression were measured in MCAO/R rats and lipopolysaccharide‐stimulated cells. Tamarixetin administration improved the neurological dysfunction and neuronal loss in MCAO/R rats. In addition, tamarixetin reduced microglial hyperactivation and proinflammatory cytokines expression in vivo and in vitro. Tamarixetin attenuated NF–κB p65 phosphorylation and promoter activity, reduced NLRP3 expression and caspase‐1 cleavage, and downregulated IL‐1β and IL‐18 secretions to suppress NLRP3 inflammasome activation. The levels of superoxide anion, hydrogen peroxide, and ROS were also suppressed by tamarixetin. The downregulation of NADP + and NADPH levels, and gp91phox expression indicated the ameliorative effects of tamarixetin on NADPH oxidase activation. In the gp91phox knockdown cells treated with lipopolysaccharide, the effects of tamarixetin on NADPH oxidase activation, ROS generation, and NLRP3 inflammasome activation were diminished. Moreover, tamarixetin protects neurons against microglial hyperactivation in vitro. Our findings support the potential of tamarixetin as a therapeutic agent for ischemic stroke, and its mechanism of action involves the inhibition of NADPH oxidase–NLRP3 inflammasome signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Bioresource Research and Development of Liaoning Province, College of Life and Health Sciences, Northeastern University, Shenyang, China.
- National Frontiers Science Center for Industrial Intelligence and Systems Optimization, Key Laboratory of Data Analytics and Optimization for Smart Industry, Ministry of Education, Northeastern University, Shenyang, Chi…
- College of Information Science and Engineering, Northeastern University, Shenyang, China.
- Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China.
- State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin, China.
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Förderung
- National Natural Science Foundation of China
- Construction Project of Liaoning Provincial Key Laboratory, China
- Fundamental Research Funds for the Central Universities
- 111 Project
- Higher Education Discipline Innovation Project
Zitieren
APA
Yang, Y., Wang, F., Fang, M., Yao, X., Xu, L., Liu, Y., Liu, Y., Liang, D., Zeng, K., Li, N., & Hou, Y. (2024). Tamarixetin ameliorates cerebral ischemia–reperfusion injury via suppressing nicotinamide adenine dinucleotide phosphate oxidase 2/nucleotide‐binding oligomerization domain like receptor family pyrin domain‐containing 3 inflammasome activation. Phytotherapy Research. https://doi.org/10.1002/ptr.8263
Vancouver
Yang Y, Wang F, Fang M, Yao X, Xu L, Liu Y, et al. Tamarixetin ameliorates cerebral ischemia–reperfusion injury via suppressing nicotinamide adenine dinucleotide phosphate oxidase 2/nucleotide‐binding oligomerization domain like receptor family pyrin domain‐containing 3 inflammasome activation. Phytotherapy Research. 2024. doi:10.1002/ptr.8263
BibTeX
@article{Yang2024,
author = {Yang, Yanqiu and Wang, Feng and Fang, Mingxia and Yao, Xiaohu and Xu, Libin and Liu, Yueyang and Liu, Yeshu and Liang, Dong and Zeng, Kewu and Li, Ning and Hou, Yue},
title = {Tamarixetin ameliorates cerebral ischemia–reperfusion injury via suppressing nicotinamide adenine dinucleotide phosphate oxidase 2/nucleotide‐binding oligomerization domain like receptor family pyrin domain‐containing 3 inflammasome activation},
journal = {Phytotherapy Research},
year = {2024},
doi = {10.1002/ptr.8263}
}
EUVIMED